Find the Perfect Plan for Your Investment Journey
I
Latest price
52 Week Range
CA$0.15 - CA$0.33
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | CA$52.64M |
EV | CA$48.11M |
Shares Outstanding | 292.42M |
Beta | 3.01 |
Analyst Rating | NOT_AVAILABLE |
Analyst Target Price | - |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | 431.60% |
EPS | 47.30% |
Operating Cash Flow | 38.00% |
Free Cash Flow | 69.20% |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -39.57% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
I
InnoCan Pharma Corporation
INNO
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Bincovich, Iris
Employees
Website
innocanpharma.comIPO Date
2019-09-25
Headquarters
1015, 926 – 5 Avenue SW, Calgary, Alberta, T2P 0N7, Canada
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved